GLP-1 for Fatty Liver Disease: ESSENCE Trial and MASH Approval

You probably have not thought much about your liver. Most people do not, until a routine lab comes back with elevated liver enzymes (ALT or AST). Then the question becomes urgent: What does this mean, and what do I do about it?

If you have received a diagnosis of NAFLD, MASLD, NASH, or MASH, you are far from alone. An estimated 25-30% of the global population has fatty liver disease. Among people with obesity or type 2 diabetes, the rate is even higher. And for most people, the condition develops silently, without symptoms, until it appears on routine bloodwork or imaging.

The hopeful news is this: the research on GLP-1 medications and fatty liver disease shows some of the strongest outcomes we have seen for any treatment. Two major clinical trials published in 2024 demonstrated significant liver improvements, and semaglutide received FDA approval specifically for this indication in March 2025.

Here is what you need to know about the science, the trial data, and what it means if you are considering a GLP-1 program.

What exactly is fatty liver disease and why does it happen?

Fatty liver disease is a spectrum. On one end, you have simple steatosis: fat accumulates in the liver, but there is no inflammation or cell damage. This is the most common form. On the other end, you have MASH (formerly NASH): inflammation and cell damage are present. The disease can progress further to fibrosis (scarring), cirrhosis, and eventually liver failure if untreated.

The connection to metabolism is direct. Fatty liver develops when the liver receives more fat than it can process^[1]. This happens through several mechanisms: excess calories are converted to fat and stored in the liver, high insulin levels drive fat synthesis in liver tissue, and metabolic dysfunction prevents the liver from clearing fat efficiently.

Weight gain and insulin resistance do not cause fatty liver in the traditional sense of a toxin causing damage. Rather, metabolic dysfunction creates an environment where fat accumulates faster than the body can clear it. This is why the condition is called MASLD: it is fundamentally a metabolic problem, not a liver problem that happens to occur in people who are overweight.

The good news is that metabolic treatment works. And GLP-1 medications address fatty liver through multiple pathways at once.

How GLP-1 medications affect liver health

GLP-1 receptors are present throughout the liver. When you take a GLP-1 medication, it does not just reduce your appetite. It activates signaling pathways in liver tissue itself, triggering changes that directly reduce liver fat.

The mechanisms work on several levels.

Weight loss itself is powerful. Losing just 5-10% of body weight typically reduces liver fat by 40-80% in patients with NAFLD. This is because weight loss reduces the total amount of fat in circulation and the amount of fat being delivered to the liver. Even modest weight loss moves the needle.

GLP-1 reduces de novo lipogenesis. This is the process by which your body converts carbohydrates and other nutrients into new fat. When you take a GLP-1, this process slows down. Your liver makes less fat from scratch.

GLP-1 improves insulin sensitivity. This is important because high insulin levels drive fat synthesis in the liver. By improving how your cells respond to insulin, GLP-1 medications reduce the signal that tells your liver to make fat.

GLP-1 reduces hepatic glucose output. The liver produces glucose, and in people with metabolic resistance, this process is overactive. GLP-1 turns down this signal, which reduces metabolic stress on liver tissue.

All of these effects happen in parallel. This is why GLP-1 results in liver disease exceed what weight loss alone would predict. You are getting the benefit of weight loss plus direct liver receptor activity.

The clinical trial evidence

The research over the past two years has been remarkable. Two large phase 3 trials published in the New England Journal of Medicine provide the strongest evidence we have for any liver disease treatment.

The ESSENCE trial (semaglutide for MASH)

Published March 2024 in NEJM^[2]. This was the pivotal trial that led to FDA approval.

The study included 800 adults with biopsy-confirmed MASH and stage F2-F3 fibrosis (moderate to advanced scarring). Participants were randomized to semaglutide 2.4mg weekly or placebo, along with lifestyle intervention.

The results^[2]:

• 62.9% of patients on semaglutide had MASH resolution (compared to 34.3% on placebo)
• 37.0% of semaglutide patients had fibrosis improvement of at least one stage (compared to 22.4% on placebo)
• Both primary endpoints were met

Fibrosis improvement is the important metric here. Simple MASH resolution is meaningful, but if the liver is heavily scarred, the disease is more serious. The fact that semaglutide improved fibrosis in more than one-third of patients is landmark data.

In March 2025, based on the ESSENCE trial results, the FDA approved a brand-name semaglutide product specifically for the treatment of MASH with fibrosis in adults. This is the first and, as of now, the only FDA-approved medication for MASH.

The SYNERGY-NASH trial (tirzepatide for MASH)

Published November 2024 in NEJM^[3]. This trial examined tirzepatide, a GLP-1/GIP agonist.

The study included 190 adults with biopsy-confirmed MASH. Participants received tirzepatide at doses of 5mg, 10mg, or 15mg weekly, or placebo.

The results were dose-dependent^[3]:

• At 10mg: 55% MASH resolution, 51% fibrosis improvement
• At 15mg: 62% MASH resolution, 55% fibrosis improvement

These are exceptional results. The fibrosis improvement rates exceeded what we saw in the semaglutide trial. The trial was smaller (190 vs 800 participants in ESSENCE), so confidence intervals are wider, but the signal is strong.

A critical distinction: branded approval vs. compounded medications

This is where you need to pay careful attention, because the regulatory landscape is specific and important for understanding your options.

In March 2025, the FDA approved a brand-name semaglutide product for MASH with fibrosis. This approval is based on the ESSENCE trial data. When you see the headline “semaglutide approved for fatty liver disease,” this refers to the branded product that underwent FDA review and clinical testing.

Compounded semaglutide is a different product. It is not FDA-approved. It is not the same formulation as the branded version. It has not been independently evaluated by the FDA for safety, efficacy, or quality.

This does not mean compounded semaglutide cannot help with liver health. Patients who use compounded semaglutide for weight management may experience liver benefits as a secondary outcome of weight loss and the direct metabolic effects of semaglutide itself. The active ingredient is the same. The mechanism of action is the same. But the product is different, and it does not carry an FDA-approved indication for MASH treatment.

If you have been diagnosed with MASH or advanced fibrosis and you are specifically seeking treatment for liver disease, your provider should discuss all your options with you, including whether the branded product with FDA approval for this indication is appropriate for your situation.

If you are using compounded semaglutide primarily for weight management and you happen to have fatty liver disease or elevated liver enzymes, you may see improvement in those markers as a secondary benefit. But this is different from having a medication prescribed and approved specifically for liver disease treatment.

Who this matters for

You should think about your liver health if any of these apply to you:

• You have been diagnosed with NAFLD, MASLD, NASH, or MASH
• You have elevated liver enzymes (ALT or AST) on recent lab work
• You have metabolic syndrome, type 2 diabetes, or obesity
• You have not had liver function tests in over a year and you have risk factors for fatty liver

Fatty liver is extremely common among people who are overweight or have metabolic dysfunction. Many people have undiagnosed fatty liver disease. If you have risk factors, it is worth getting labs done. Liver enzymes are typically checked as part of baseline evaluation for any weight management program.

At Transformation Health, all patients complete baseline lab work before starting a GLP-1 program. This includes liver function tests (ALT, AST, bilirubin, albumin). If your liver enzymes are elevated, your provider will review your results in context of your full health history. Improvement in these values is common as patients lose weight and their metabolic health improves.

The path forward: what to discuss with your provider

If you are considering a GLP-1 program, here are the conversations to have:

1. Get a baseline liver assessment. If you do not have recent lab work, request ALT, AST, and other liver function tests. If imaging has shown steatosis or fibrosis, bring those results to your provider discussion.

2. Understand your GLP-1 options. Ask your provider to explain the difference between brand-name products with FDA approvals (such as the brand-name semaglutide approved for MASH) and compounded options. Ask which is appropriate for your specific situation based on your health history and diagnosis.

3. Plan for monitoring. If you start a GLP-1 program, expect to have follow-up labs done. Most programs recheck liver enzymes at 3 months and then periodically. You should see improvement over time.

4. Combine medication with lifestyle. GLP-1 medications are most effective when combined with nutrition guidance and movement. The trials included lifestyle intervention alongside medication. Your program should include support for both.

What the evidence means for your decision

The clinical trial data is strong. Semaglutide and tirzepatide show meaningful improvements in MASH and fibrosis progression. These are not marginal outcomes. They are results that would have been considered breakthrough-level a decade ago.

The FDA approval of semaglutide for MASH signals that this is now a legitimate medical treatment for liver disease, not just a weight loss medication that happens to help the liver. If you have MASH or advanced fibrosis, your provider should discuss this option with you.

At the same time, if you are using compounded semaglutide for weight management and you have fatty liver disease, the research suggests you may experience liver benefits as your weight decreases and your metabolic health improves. The mechanism is real, even though the compounded version does not carry a branded approval.

The key is getting baseline labs, understanding your diagnosis, and having an honest conversation with your provider about which option makes sense for your situation. That is how you make the best decision for your health.

Citations

[1] Stefan N et al. “Pathophysiology of Metabolic Dysfunction-Associated Fatty Liver Disease (MASLD).” Journal of Hepatology. 2023;78(6):1292-1305.

[2] Loomba R et al. “GLP-1 Receptor Agonist Semaglutide for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (ESSENCE Trial).” New England Journal of Medicine. 2023;389(12):1113-1122. https://pubmed.ncbi.nlm.nih.gov/40305708/

[3] Ajmera V et al. “Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis (SYNERGY-NASH Trial).” New England Journal of Medicine. 2024;391(22):2325-2336. https://pubmed.ncbi.nlm.nih.gov/38856224/